Betashares Global Healthcare Currency Hedged ETF (DRUG) Review & Analysis

MER Β· #330 of 514AUM Β· Top 50%1Y Return Β· Top 10%3Y Return Β· #205 of 3005Y Return Β· #129 of 225
What's new this monthData to 30 September 2026
  • βˆ’0.4% in September (total return), behind the median international shares ETF at +0.0%.
  • Investors withdrew a net $0.9m (-0.5% of the fund).
  • The unit price closed the month at $9.00, 3% below its 12-month high (range $7.64 to $9.27).

About DRUG

DRUG is an international shares ETF from Betashares, listed on the ASX since August 2016. With $173m under management it is number 112 of 254 international shares ETFs by size. The management fee is 0.57% a year, about $57 on every $10,000 invested, dearer than the typical international shares ETF at 0.55%.

Its largest holdings are Eli Lilly & Co, Johnson & Johnson and AbbVie Inc, and the top 10 make up 53% of the fund. By sector it leans towards health care (95%) and information technology (4%). United States is the biggest country exposure at 81%.

Over five years it has returned +4.9% a year including distributions, against +8.8% for the median international shares ETF. With its focus on healthcare, it is the kind of fund many investors use as a smaller satellite holding alongside a diversified core.

DRUG distributions and dividend dates

DRUG pays distributions yearly, usually going ex-distribution in July, with payment about 15 days after the ex-date. (Pattern estimated from recent payments.)

The latest distribution was $0.3121 per unit (0% franked), ex-distribution on 1 July 2026 and paid on 16 July 2026. To receive it you need to own DRUG before the ex-date.

Its distribution yield over the past 12 months is about 3.5%. Distributions vary and past payments are not a guide to future ones.

From ASX announcements, updated nightly. See every ETF in the dividend calendar.

Compare DRUG with

DRUG price by TradingView

Stock CodeDRUG
Fund ManagerBetashares
Asset ClassInternational shares
AUM$173m
MER (%)0.57%
Net flows (Sep)βˆ’$0.9m
Last Price$9.00
52-Week Range$7.64 – $9.27
Bid/Ask Spread0.18%
Listing Date08/08/2016
ExchangeASX
IndexNot yet in our data. See the PDS
Issuer websiteBetashares β†—

Performance (% return)

-0%9%18%27%1M-0.4%1Y21.1%3Y23.7%5Y27.2%
1 monthβˆ’0.4%
1 year+21.1%
3 years p.a.+7.3%
5 years p.a.+4.9%

$10,000 invested…

1 year ago$12,1073 years ago$12,3705 years ago$12,722

Value at 30 September 2026 with distributions reinvested, before tax and brokerage.

Total returns including distributions, to 30 September 2026. 1M, 1Y, 3Y and 5Y bars are cumulative.

DRUG at a glance: strengths and things to watch

πŸ‘ Strengths

  • Long track record. Listed since 2016, through several market cycles.
  • In an uptrend. Its price has been trending up since 21 October (as at 14 November).

⚠️ Things to watch

  • Behind its peers. +4.9% a year over 5 years, against +8.8% for the median international shares ETF.
  • Concentrated. The top 10 holdings make up 53% of the fund, so a few companies drive the result.

Worked out from DRUG's fees, size, flows, returns and trend against the 257 international shares ETFs in Australia, to 30 September 2026. General information, not a recommendation.

Joshua StegaetfadviserTrend check
Uptrend since 21 Oct 2026

DRUG is in an uptrend. Here's why that matters.

DRUG's price is above its 20-day average and its 10, 20, 50 and 200-day averages are stacked upward. The trend is on investors' side. Its price is at or near its 12-month high.

Why it matters: Uptrends are when satellite ETFs tend to do their best work. The key is knowing when the trend breaks, so gains aren't handed back.

At ETF Adviser the core of a portfolio stays invested through every stage, and satellite ETFs are only bought in an uptrend. Members get a weekly update on which ETFs are breaking out of a base and which trends have broken.

Nov 25Feb 26May 26Aug 26Nov 26
UptrendBaseDowntrend

DRUG weekly price, past 12 months, shaded by trend stage. Stage as at 14 November 2026, updated weekly. A technical label, not a recommendation.

DRUG vs its benchmark

How DRUG has done against the Nasdaq Global ex-Australia Healthcare AUD Hedged Index, after fees. For an index fund, a small shortfall roughly the size of the fee is normal.

DRUGBenchmarkDifference
1 year+23.79%+24.56%-0.77%
3 years p.a.+12.00%+12.56%-0.56%
5 years p.a.+6.10%+6.57%-0.47%

Issuer figures to 30 October 2026, fund returns after fees. Source: Betashares. Compare more ETFs vs their benchmark β†’

Investment Focus

Exposure Regions

Global

Themes & Sectors

Currency hedgedHealthcare

Portfolio Breakdown

Top 10 holdings (52.7% of the fund)

SymbolCompany% assets
LLY9.06%
JNJ7.60%
ABBV6.95%
MRK4.92%
UNH4.88%
AZN4.26%
ROP4.14%
NOVN3.93%
TMO3.74%
AMGN3.23%

Sector breakdown

  • Health Care95.2%
  • Information Technology4.2%
  • Consumer Staples0.6%

Country breakdown

  • United States80.5%
  • Switzerland6.0%
  • United Kingdom4.3%
  • Japan3.0%
  • DK2.0%
  • France1.0%
  • Hong Kong0.8%
  • Germany0.8%
  • Other1.5%

Holdings from the issuer's published portfolio as at 30 October 2026. Breakdowns are based on the largest 55 positions, covering 99% of the fund. Compare DRUG's holdings with other ETFs β†’

Best-endeavours estimate. Built from each issuer's published holdings, which may be weeks or months old, may cover only part of a fund (some publish only their top 10) and are matched by company name. Figures may be incomplete or inaccurate. Check the issuer's website and PDS before relying on them. General information only.

Similar ETFs

CodeNameSame holdingsMERAUM1Y3Y p.a.5Y p.a.
IXJiShares Global Healthcare ETF
73%
0.41%$1.5bn+14.9%+6.2%+5.9%
HLTHVanEck Global Healthcare Leaders ETF
22%
0.45%$59m+5.5%+6.3%βˆ’0.1%
VGADVanguard MSCI Index International Shares (Hedged) ETF Currency hedged
8%
0.21%$7.9bn+17.1%+19.8%+10.8%
IHVViShares S&P 500 (AUD Hedged) ETF Currency hedged
10%
0.10%$4.3bn+15.4%+21.0%+10.9%
DFGHDimensional Global Core Equity Trust (AUD Hedged Class) – Active ETF Currency hedged–0.36%$4.2bn+18.2%––
HGBLBetashares Global Shares Currency Hedged ETF Currency hedged
10%
0.11%$3.0bn+17.4%+20.6%–

Same holdings is the share of DRUG's money in companies the other ETF also holds, weighted by size. Most similar first, then ETFs in the same category. See every ETF like DRUG β†’

DRUG vs its closest alternatives

What actually differs between DRUG and the ETFs most like it. Data to 30 Sep 2026.

IXJ iShares Global Healthcare ETF

  • They share 73% of their holdings: a lot of doubling up.
  • IXJ is cheaper (0.41% vs 0.57%), worth about $10,607 on $100,000 over 20 years.
  • Over 3 years, a year: DRUG +7.3%, IXJ +6.2% (DRUG ahead by 1.1 percentage points).
  • IXJ is about 9 times larger ($1.5bn vs $173m), which usually means tighter trading spreads.
  • Different structure: DRUG is currency hedged, IXJ is a standard fund.

Full DRUG vs IXJ comparison β†’

HLTH VanEck Global Healthcare Leaders ETF

  • They share 22% of their holdings: some overlap.
  • HLTH is cheaper (0.45% vs 0.57%), worth about $7,927 on $100,000 over 20 years.
  • Over 3 years, a year: DRUG +7.3%, HLTH +6.3% (DRUG ahead by 1.0 percentage points).
  • DRUG is about 3 times larger ($173m vs $59m), which usually means tighter trading spreads.
  • Different structure: DRUG is currency hedged, HLTH is a standard fund.

Compare DRUG and HLTH side by side β†’

VGAD Vanguard MSCI Index International Shares (Hedged) ETF

  • They share 8% of their holdings: mostly different companies.
  • VGAD is cheaper (0.21% vs 0.57%), worth about $24,298 on $100,000 over 20 years.
  • Over 3 years, a year: DRUG +7.3%, VGAD +19.8% (VGAD ahead by 12.5 percentage points).
  • VGAD is much larger ($7.9bn vs $173m), which usually means tighter trading spreads.

Compare DRUG and VGAD side by side β†’

General information only. Past performance is not a reliable indicator of future performance.

Popular comparisons

IXJ vs DRUG

Related Reads

DRUG FAQs

What is the fee for DRUG?

DRUG charges a management fee (MER) of 0.57% a year, according to the TMX Australia monthly funds report as at 30 September 2026.

How big is DRUG?

DRUG had $173m in funds under management as at 30 September 2026.

How has DRUG performed?

DRUG returned +21.1% over the year to 30 September 2026 (total return, including distributions). Over three years it returned +7.3% a year. Past performance is not a reliable indicator of future performance.

Who manages DRUG?

DRUG is managed by Betashares and has been listed since August 2016.

Is DRUG franked?

Generally no. DRUG invests outside Australia, so its distributions carry little or no franking credits. Franking comes from Australian companies that have paid tax here.

What does DRUG hold?

DRUG's largest holdings are Eli Lilly & Co (9.1%), Johnson & Johnson (7.6%), AbbVie Inc (7.0%), Merck & Co Inc (4.9%), UnitedHealth Group Inc (4.9%). It holds about 55 investments in total. The biggest sector is health care at 94%. Holdings as at 30 October 2026.

Is DRUG currency hedged?

Yes. DRUG is currency hedged, so changes in the Australian dollar have little effect on its returns. You get the return of the underlying investments in their local currency, less a small cost of hedging.

Disclaimer

This review is general information only and does not take into account your objectives, financial situation or needs. Consider the Betashares product disclosure statement (PDS) and target market determination (TMD) before investing. Past performance is not a reliable indicator of future performance.